Furthermore, in NPC xenograft mouse models, oral administration of vitexin at 30 mg/kg for two weeks reduces tumor growth by decreasing the expression levels of p-p65 and Cyclin D1 [57]. Here, CCND1 is linked to nasopharyngeal carcinoma.